An Observational Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications

NCT04322188 · clinicaltrials.gov ↗

COMPLETED

Status

220

Enrollment

OTHER

Sponsor class

Conditions

Severe Acute Respiratory Syndrome (ARDS) Secondary to SARS-COV-2 Infection

Interventions

OTHER:

Sponsor

A.O. Ospedale Papa Giovanni XXIII